Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy.
biomarker
encephalitis
neurofilament
neurological disorders
oncology
paraneoplastic syndromes
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
27
11
2020
accepted:
15
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
13
8
2021
Statut:
ppublish
Résumé
Neurological immune-mediated side effects are rare but often severe complications of immune checkpoint inhibitor (ICI) treatment. This report describes a severe case of nivolumab/ipilimumab-associated glutamic acid decarboxylase 65-positive autoimmune encephalitis. It proposes neurofilament light chain levels, a biomarker indicating axonal damage, in the cerebrospinal fluid and serum as a putative novel biomarker for this diagnostically and therapeutically challenging entity with an often unfavorable outcome. Additionally, we provide an overview of previous reports of patients developing autoimmune encephalitis under ICI treatment.
Substances chimiques
Immune Checkpoint Inhibitors
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Glutamate Decarboxylase
EC 4.1.1.15
glutamate decarboxylase 2
EC 4.1.1.15
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1089Informations de copyright
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Guerin J, Watson RE, Carr CM, Liebo GB, Kotsenas AL. Autoimmune epilepsy: findings on MRI and FDG-PET. Br J Radiol. 2019;92(1093):20170869.
Gagnon M-M, Savard M. Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature. Can J Neurol Sci. 2016;43(4):486-493.
Vogrig A, Muñiz-Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020;91(7):772-778.
Khalil M, Teunissen CE, Otto M. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589.
Siller N, Kuhle J, Muthuraman M. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25(5):678-686.
Constantinescu R, Krýsl D, Bergquist F. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol. 2016;23(4):796-806.
Körtvelyessy P, Prüss H, Thurner L. Biomarkers of neurodegeneration in autoimmune-mediated encephalitis. Front Neurol. 2018;9:668.
Mariotto S, Gajofatto A, Zuliani L. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. J Neurol. 2019;266(7):1643-1648.